Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

MLA

Silvestri, Valentina, et al. “Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).” JAMA Oncology, vol. 6, no. 8, Aug. 2020, pp. 1218–30. EBSCOhost, https://doi.org/10.1001/jamaoncol.2020.2134.

APA

Silvestri, V., Leslie, G., Barnes, D. R., Agnarsson, B. A., Aittomäki, K., Alducci, E., Andrulis, I. L., Barkardottir, R. B., Barroso, A., Barrowdale, D., Benitez, J., Bonanni, B., Borg, A., Buys, S. S., Caldés, T., Caligo, M. A., Capalbo, C., Campbell, I., Chung, W. K., … Ottini, L. (2020). Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncology, 6(8), 1218–1230. https://doi.org/10.1001/jamaoncol.2020.2134

Chicago

Silvestri, Valentina, Goska Leslie, Daniel R Barnes, Bjarni A Agnarsson, Kristiina Aittomäki, Elisa Alducci, Irene L Andrulis, et al. 2020. “Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).” JAMA Oncology 6 (8): 1218–30. doi:10.1001/jamaoncol.2020.2134.